⏳ Fetching live dividend data...
Home › Calculator › SLRX Dividend Calculator 2026
Salarius Pharmaceuticals, Inc. · NASDAQ
Price: $0.84 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
SLRX is not a dividend-focused stock
SLRX pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Salarius Pharmaceuticals, Inc. (SLRX) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with SP-2577 and related compounds. A collaboration with HLB Life Sciences grants rights for the comprehensive development, production, and commercialization of the drug in South Korea. Furthermore, Salarius partners with the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate product development activities. A research collaboration with the Cancer Epigenetics Institute at Fox Chase Cancer Center aims to uncover new indications and biomarkers for SP-2577. Corporate operations are managed from its headquarters in Houston, Texas.
No. Salarius Pharmaceuticals, Inc. (SLRX) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. SLRX has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SLRX position with:
Real after-tax yield depends on where you live and how you hold SLRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SLRX pays quarterly — 4 times per year. Ex-div: —.
How SLRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SLRX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2020-08-21 | 4,000 | $0.98 | $3.9K | ||
| Buy | 2020-02-11 | 4,350 | $1.15 | $5.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Compare SLRX with peers: SLRX vs ATXI · SLRX vs ENVB · SLRX vs GTBP
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SLRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Salarius Pharmaceuticals, Inc. (SLRX) is currently trading at $0.84, 98% below its 52-week high. It does not currently pay a regular dividend.
Salarius Pharmaceuticals, Inc. (SLRX) is a healthcare stock trading at $0.84. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever